Free Trial
NYSE:GKOS

Glaukos (GKOS) Stock Price, News & Analysis

Glaukos logo
$151.22 +2.86 (+1.93%)
(As of 12/24/2024 04:45 PM ET)

About Glaukos Stock (NYSE:GKOS)

Key Stats

Today's Range
$148.65
$151.92
50-Day Range
$127.69
$151.22
52-Week Range
$74.75
$151.92
Volume
239,731 shs
Average Volume
574,744 shs
Market Capitalization
$8.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$145.92
Consensus Rating
Moderate Buy

Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Glaukos Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
83rd Percentile Overall Score

GKOS MarketRank™: 

Glaukos scored higher than 83% of companies evaluated by MarketBeat, and ranked 179th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 10 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Glaukos has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Glaukos' stock forecast and price target.
  • Earnings Growth

    Earnings for Glaukos are expected to grow in the coming year, from ($1.89) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Glaukos is -50.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Glaukos is -50.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Glaukos has a P/B Ratio of 15.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.82% of the outstanding shares of Glaukos have been sold short.
  • Short Interest Ratio / Days to Cover

    Glaukos has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Glaukos has recently decreased by 5.34%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Glaukos does not currently pay a dividend.

  • Dividend Growth

    Glaukos does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.82% of the outstanding shares of Glaukos have been sold short.
  • Short Interest Ratio / Days to Cover

    Glaukos has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Glaukos has recently decreased by 5.34%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Glaukos has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Glaukos this week, compared to 7 articles on an average week.
  • MarketBeat Follows

    2 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,605,678.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Glaukos is held by insiders.

  • Percentage Held by Institutions

    99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Glaukos' insider trading history.
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

Glaukos Co. (NYSE:GKOS) Director Sells $1,502,800.00 in Stock
Mysterious drone activity triggers massive 1,366% surge
If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.
Glaukos submits NDA to U.S. FDA for Epioxa to treat keratoconus
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
Glaukos (NYSE:GKOS) Hits New 12-Month High on Analyst Upgrade
See More Headlines

GKOS Stock Analysis - Frequently Asked Questions

Glaukos' stock was trading at $79.49 at the beginning of the year. Since then, GKOS stock has increased by 90.2% and is now trading at $151.22.
View the best growth stocks for 2024 here
.

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings results on Monday, November, 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. The firm's quarterly revenue was up 23.9% on a year-over-year basis.

Glaukos (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Top institutional investors of Glaukos include FMR LLC (11.94%), Wellington Management Group LLP (3.96%), State Street Corp (3.54%) and Brown Capital Management LLC (2.96%). Insiders that own company stock include Joseph E Gilliam, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner.
View institutional ownership trends
.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

Last Earnings
11/04/2024
Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Employees
780
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$145.92
High Stock Price Target
$185.00
Low Stock Price Target
$100.00
Potential Upside/Downside
-3.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-134,660,000.00
Pretax Margin
-41.24%

Debt

Sales & Book Value

Annual Sales
$360.35 million
Book Value
$9.46 per share

Miscellaneous

Free Float
51,608,000
Market Cap
$8.34 billion
Optionable
Optionable
Beta
1.03

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:GKOS) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners